Let's talk medical research

Osteoarthritis (OA) is the most common type of arthritis that impacts the knee joint. It is a result of the knee cartilage progressively wearing away, which can lead to difficulty moving, stiffness, and weakness, all of which worsen with time. Knee OA makes up 80% of diagnosed osteoarthritis cases, impacting 19% of adults over the age of 45.

We’re always excited to get a chance to connect with people in the clinical trial industry, and this year, we’re thrilled to share that we’ll be attending SCOPE 2023 from February 6 to 9 in Orlando, Florida.

Osteoporosis, translated directly to “porous bone,” is a condition that impacts approximately 10 million Americans. The human body is constantly producing bone cells, but they are constantly being lost as well — and when the cells are being dissolved faster than they are being produced, weakness can result. Below, we’ll be taking a closer look at what osteoporosis is, what causes it, and how ...

Increasing diversity, equity, and inclusion (DEI) in clinical trials is a topic that has received a lot of attention in recent years, especially on the heels of the most recent guidance from the Food and Drug Administration — but it is still an area ripe for improvement.

Oftentimes, clinical trial enrollment statistics paint a grim picture of the medical research landscape. A frequently-cited statistic is that approximately 80% of clinical trials are delayed or closed because of problems with recruitment, and there are other troubling statistics such as:

National Glaucoma Awareness Month is a campaign aimed at increasing awareness around glaucoma, a leading cause of vision loss and blindness with no early warning signs.

Hemophilia is a disease in which the blood does not clot properly. It is rare and typically hereditary, often leading to spontaneous or excessive bleeding, especially following injuries or surgery, and internal bleeding can be a major risk factor. Below, we’re exploring a few hemophilia facts many people may not know.

Alzheimer’s disease is the most common type of dementia in the United States, impacting around 6.2 million people above the age of 65. Since it was first observed in the early 1900s, a lot of information has been uncovered through medical research.

As a digital company, Antidote does not produce goods or services that have a major environmental impact — however, we understand that small changes still have a big impact.

Antidote is dedicated to accelerating medical research by bringing sponsors and patients together. Through our clinical trial matching software, strategic partner relationships, extensive database, and patient-centric focus, we’re transforming the way that patients connect with research — and continually measuring our progress so we can refine the process.